Alpha Cognition Inc..
ACOG.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Alpha Cognition Inc. is a biopharmaceutical company committed to developing therapies for neurodegenerative diseases, including Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS). The company's primary focus is on developing innovative treatments to improve cognitive function and overall qu...Show More
Better Health for All
-10
Alpha Cognition's core product, ZUNVEYL (benzgalantamine), is an FDA-approved treatment for mild-to-moderate Alzheimer's disease, which clinical studies indicate improves cognition and reduces the risk of severe dementia and mortality.
1
The company's business model is entirely focused on developing therapies for neurodegenerative diseases, with no evidence of revenue from products with negative health outcomes.
2
Clinical trials for ZUNVEYL reported a low incidence of adverse events at 2% of patients, which translates to 20,000 adverse events per million users.
3
The company's product, ALPHA-1062, is a patented new chemical entity.
4
While the company aims to work with healthcare providers, payers, and caregivers to enhance education and streamline access, suggesting an intent to improve access, specific details on the extent of reach to vulnerable populations are not provided.
5
The company's articles detail the mechanism of action, clinical trial results, and FDA approval process, but also list potential serious side effects for ZUNVEYL, including serious skin reactions and cardiovascular issues, without providing specific rates for these serious events or detailing how these risks are communicated to patients.
6
Fair Money & Economic Opportunity
0
Alpha Cognition Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
1
The company does not offer lending, deposit, or other financial services to consumers.
2
As such, all Key Performance Indicators (KPIs) under the 'Fair Money & Economic Opportunity' value, which are designed for financial institutions, are not applicable to Alpha Cognition Inc. and are scored as 0 according to the rubric's explicit 'not applicable' thresholds.
3
Fair Pay & Worker Respect
0
A single late Form 3 filing by the interim CFO was noted.
1
This is a securities filing and not a substantiated labor-law or human-rights violation. No other labor-law or human-rights violations are mentioned in the provided articles.
2
For all other KPIs, the articles explicitly state insufficient data is available or do not provide the necessary quantitative metrics for assessment.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Alpha Cognition Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete, or quantitative data points were found in the provided articles to assess Alpha Cognition Inc. against any of the KPIs for the 'Honest & Fair Business' ethical value. The articles primarily list governance documents and legal disclaimers without providing performance metrics, regulatory actions, financial details, or specific policy implementation and effectiveness data.
1
Kind to Animals
0
No evidence available to assess Alpha Cognition Inc. on Kind to Animals.
No War, No Weapons
-50
Alpha Cognition Inc. is developing ALPHA-1062, a drug candidate for mild traumatic brain injury (mTBI) that targets military personnel and also addresses Alzheimer's disease.
1
The company received a $750K grant from the Department of Defense (DoD) and is collaborating with the VA for this research.
2
The estimated market for mTBI in military and civilian populations is $2.5-5B, while the global Alzheimer's drug market is $50B, indicating a majority civilian focus for this dual-use technology.
3
Regarding conflict minerals, Alpha Wire, a company mentioned in one article, is conducting due diligence on supplier conflict mineral sourcing and states that some smelters are flagged as operating in high-risk areas but their use is not prohibited.
4
No specific quantitative data on conflict mineral sourcing for Alpha Cognition Inc. is provided, nor is there evidence of a verified conflict-free supply chain percentage.
5
Planet-Friendly Business
0
No specific, quantitative evidence regarding ACOG.US's planet-friendly business practices, environmental performance, or sustainability initiatives was found in the provided articles. The articles primarily focus on the company's financial performance, operational updates, and clinical trial data for its drug candidates. General discussions about ESG scores or potential ESG risks for ACOG.US were noted, but without concrete data points, actions, or policies, no KPIs could be scored.
1
Respect for Cultures & Communities
0
No specific, concrete data points or facts were found in the provided articles regarding Alpha Cognition Inc.'s performance on any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily discuss drug approvals, financial information, legal disclaimers, governance documents, and consent forms, explicitly stating that they do not contain relevant information for this ethical value.
Safe & Smart Tech
-60
The company provides users with various privacy rights, including access, correction, deletion, restriction of processing, and withdrawal of consent, along with options to opt out of email, text messages, mobile device tracking, and personalized advertising.
1
However, the services are not directed to children under 18, and the company has no actual knowledge of selling or sharing personal information of individuals under 16.
2
For authentication, identity verification tools are used to ensure authorized environment access, but there is no information on the availability of multi-factor authentication (MFA) or the strength of password policies.
3
The company conducts ongoing vulnerability assessments and debugs to identify and repair errors.
4
It reports its cybersecurity risk management and governance process in a yearly 10-K filing and states it collects personal information where required to comply with regulatory requirements, including federal, state, and foreign data protection laws, HIPAA, and GDPR.
5
Zero Waste & Sustainable Products
0
The provided articles discuss general strategies and challenges for sustainable packaging and waste reduction within the pharmaceutical industry. However, none of the articles contain specific, quantitative data or concrete actions directly attributable to ACOG.US regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
Therefore, no KPIs can be scored based on the evidence provided.